Atrium Therapeutics, Inc. Stock Price

NasdaqGS:RNA Community·US$243.1m Market Cap

0 Narratives written by author
0 Comments on narratives written by author
0 Fair Values set on narratives written by author

Create a narrative

RNA Share Price Performance

US$16.54

1.79 (12.14%)

US$16.54

1.79 (12.14%)

US$16.54

Thu, 5 Mar 26

Share Pricen/a

RNA Community Narratives

There are no narratives available yet.

Create a narrative

There are no community narratives available.

Trending Discussion

Snowflake Analysis

Very low risk with weak fundamentals.

2 Risks

0 Rewards

View Full Analysis

Atrium Therapeutics, Inc. Key Details

Last Reported Earnings

n/a

Next Reporting Earnings

n/a

: 0
: 0%
: 0%
: 0%

View Full Analysis

About RNA

Founded: 2025
Employees: n/a
CEO: Kathleen Gallagher
Website: n/a

Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivery of RNA therapeutics to the heart to transform the care for people living with cardiomyopathies. The company offers ATR 1072, is a potentially disease-modifying treatment for PRKAG2 syndrome; ATR 1086 for phospholamban (PLN) cardiomyopathy. The company also provides cardiac disease pipeline, includes PRKAG2 syndrome, PLN cardiomyopathy. The company was formerly known as Bryce Therapeutics, Inc. Atrium Therapeutics, Inc. was incorporated in 2025 and is headquartered in San Diego, California. Atrium Therapeutics, Inc. operates as a subsidiary of Avidity Biosciences, Inc.